Solid Tumor Cancer

Today, treatments for blood cancer fall into three categories: chemotherapy, radiation, and bone marrow transplants (BMT). BMT (with or without CAR-T) is the most effective option, but carries significant cost and treatment complications.

Today’s allogeneic BMT approaches include a marked incidence of both GvHD and viral infections, and can require prolonged post-transplant immune suppression treatment. Though some companies are developing allogeneic CAR-T to treat solid tumor cancer, none have shown that they are able to deliver an approach which is both safe and effective. While initial overall response rates can be very high, to date even the most successful treatments have not demonstrated long term efficacy, and the potential for relapse is significant.

Cell Source’s Veto Cell-based treatment protocols include several major advances over the current treatment standards. Pre-BMT reduced intensity conditioning (RIC) translates to healthier patients (and makes BMT a safe treatment option for already weakened or sick patients). Removal of T-cells from the donor BMT prior to delivery to the recipient reduces or eliminates the risk of life-threatening Graft vs. Host Disease (GvHD). The inclusion of Veto Cells (with or without CAR-T and anti-viral capabilities) ensures the transplanted bone marrow will be accepted by the recipient, leading to long-term, permanent immune system modification (and with CAR-T, long-lasting effectiveness against cancer relapse).

Cell Source plans to initiate pre-clinical trials utilizing Veto Cells against solid tumor cancer.

According to the Journal of Oncology Practice, by 2020, 18.2 million Americans — roughly 1 in 19 people — will be cancer patients or cancer survivors, up from 11.7 million (1 in 26) in 2005.

The global solid tumor cancer treatment market was valued at $121.3 billion in 2018 and is expected to reach $424.6 billion by 2027, expanding at a CAGR of 15.0% from 2019 to 2027 (source: Research and Markets).